Compare Nebius Group NV (NBIS) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nebius Group NV vs Pfizer Inc — how do they compare? Nebius Group NV trades at $225.31 (market cap $59.73B), while Pfizer Inc trades at $27.72 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 2.7× Nebius Group NV's market cap, and Pfizer Inc pays a 6.18% dividend while Nebius Group NV pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nebius Group NV for 24 Days and Pfizer Inc for 158 Days on average.
| NBIS | PFE | |
|---|---|---|
Market Cap | $59.73B | $158.56B |
Volume | 21,563,700 | 44,138,282 |
Sector | Technology | Health |
52-Week High | $286.69 | $29.02 |
52-Week Low | $73.87 | $23.67 |
Typical Hold Time | 24 Days | 158 Days |
Enterprise Value | $61.86B | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NBIS trades at $237.07, down 5.08% today, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company shows strong revenue growth with 2026 projections reaching $1.4B, though profitability remains challenged with a net margin of 3.13%. Recent acquisitions like Inferize and partnerships with Nvidia and Palantir position NBIS as a key player in AI infrastructure, supported by an 81.82% analyst buy rating and $272.70 consensus price target.
Outlook: NBIS benefits from AI demand and a $37B backlog but faces execution risks from heavy spending ($11.4B investing outflow in 2026) and high valuations (P/E 845). Insider selling and competitive pressures from hyperscalers pose near-term headwinds, though institutional bullishness suggests long-term growth potential if operational targets are met.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
